Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion
about
The MET axis as a therapeutic target.Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor TFAK and paxillin, two potential targets in pancreatic cancerc-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic CascadeRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsMET molecular mechanisms and therapies in lung cancerPaxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic diseaseProteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology databasePaxillin mediates sensing of physical cues and regulates directional cell motility by controlling lamellipodia positioningCalpain-mediated proteolysis of paxillin negatively regulates focal adhesion dynamics and cell migration.The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerRole of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.Significance of talin in cancer progression and metastasis.MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.Emerging role of paxillin-PKL in regulation of cell adhesion, polarity and migrationAbnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer.Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma.p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancerBcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer.A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cellsHOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinomaPaxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87.Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer PatientsDeciphering Mode of Action of Functionally Important Regions in the Intrinsically Disordered Paxillin (Residues 1-313) Using Its Interaction with FAT (Focal Adhesion Targeting Domain of Focal Adhesion Kinase).Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation.Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic valueNovel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.Diverse roles for the paxillin family of proteins in cancer.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.MET as a target for treatment of chest tumorsMET pathway as a therapeutic target.Paxillin: a crossroad in pathological cell migrationPaxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression.MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
P2860
Q24609682-B8C9151B-6FA1-4522-BA92-8E731FC9D0FDQ24646348-EC5A3989-F8F9-48A4-A32F-C99561A9E666Q26765360-7BB4297A-A392-49F5-A557-F16C43441C5CQ26998420-97A46429-0476-41E3-8715-3CD04976EEADQ27027957-897A0424-3C0C-4120-B435-B96A6347D826Q28272688-5EC8A31B-C022-49B5-A203-1A1F4798EF6EQ28297509-C0E85CA6-4FE0-4594-B4DA-FFB14C158972Q28391454-ECCCF9D1-E527-4424-8CDD-0539ECD09F6EQ28478399-D6971864-E7F5-409D-A3FE-C79A32A9C499Q30427752-138FB021-C66A-450F-85F5-56E2DD8FFA05Q30494514-7E2E4CF4-AD03-42A7-AC4C-F1BB03F94AE0Q30497846-410E3B03-35C6-4BF3-A9F3-69C34C9E465DQ30542819-4C2420BE-4432-43C1-B7C1-D253D20BD8E8Q31154012-6C824D46-0041-403C-AD6C-B380ED537A68Q33763551-53BC8969-B438-426B-87FB-8E36B9620AE0Q34182679-59C28348-1B89-49D4-AF8F-B315ADFF1D52Q34219445-218700B6-E820-43F8-A5AD-F691CA02F60EQ34493542-4E62D2C9-4462-4324-904C-529D2AB0D024Q34500644-8E1BCDD8-C424-44D4-88E8-203F986F0D36Q34721988-37D0A8F0-F402-447B-A7AB-9D0CAE8D5974Q34984681-CFF50FD2-7F7D-4B81-AF95-3FB891686018Q35146597-920311C3-7422-43D6-833E-45A3C33B9409Q35146937-8749B210-2604-4B2D-96CF-9D74B7B73032Q35206363-4ACF0DA0-5085-4B83-8E8F-EC5714D5C60AQ35349490-2F442D42-A9A4-490C-B4F8-8F663A0D3F0DQ35357838-FE50336E-921B-4885-9D39-C36F4374CF3CQ35413993-713F6ECB-76C2-4951-B711-D10E7FBE06B3Q35832209-CCC558A8-1EC2-4DFF-BE93-884FDC409665Q35871428-18516488-A22E-4A71-985F-9D23FC9100EBQ35940252-AE5511FF-977B-4FE3-ABFA-830ABA29FB82Q36068321-3D9132EC-801D-4588-8238-70B79F845EF1Q36095220-1A0997E2-D2D0-406B-86EF-5E4E29F6201EQ36212445-62588832-545A-46F0-9A71-32EE60907106Q36443392-16E2B55B-E0E6-4F68-8C97-62BB401BC677Q37051546-09E26BDE-E3E2-4F6F-A5E2-6CB34272F2BAQ37232416-664E81F3-52F7-4107-8911-455184533083Q37427292-7CBA5A64-4307-4FA6-ABEB-C2977243BCD4Q37650990-3BD04629-9553-448B-B661-8861B6977995Q37702693-E82EF8DE-970C-4C5F-8368-1EE24AD81569Q38389999-A69E775D-4FC3-44A5-B9FE-36726F3D4A97
P2860
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Paxillin is a target for somat ...... s for cell growth and invasion
@ast
Paxillin is a target for somat ...... s for cell growth and invasion
@en
Paxillin is a target for somat ...... s for cell growth and invasion
@nl
type
label
Paxillin is a target for somat ...... s for cell growth and invasion
@ast
Paxillin is a target for somat ...... s for cell growth and invasion
@en
Paxillin is a target for somat ...... s for cell growth and invasion
@nl
prefLabel
Paxillin is a target for somat ...... s for cell growth and invasion
@ast
Paxillin is a target for somat ...... s for cell growth and invasion
@en
Paxillin is a target for somat ...... s for cell growth and invasion
@nl
P2093
P2860
P50
P3181
P1433
P1476
Paxillin is a target for somat ...... s for cell growth and invasion
@en
P2093
A Craig Mackinnon
Aliya N Husain
Gavin J Gordon
Hanna Surawska
John Minna
Leonardo Faoro
Lioubov Soulii
Livia L Szeto
Luc Girard
Maria S Tretiakova
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-07-1998
P407
P577
2008-01-01T00:00:00Z